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Introduction
M
alignant  obstructive  jaundice  is  a  poor 
prognostic  disease  with  important 
consequences for the patient’s lifestyle and survival. 
Most  of  the  patients  will  die  during  the  first  six 
months after diagnosis.
There  is  no  curative  therapy  for  the  disease, 
but stenting and drainage of the biliary tree have 
been proven as a safe method with few technical 
complications. Percutaneous transhepatic insertion 
of  metallic  stents  is  now  a  reliable  method  for 
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Background and Aims: Palliation therapy is the only available therapeutic method for most patients with tumor-induced 
obstructive jaundice. Metallic stents are now performed percutaneously as an alternative route to the endoscopic ap-
proach. It is widely accepted because of its safety, good patency rate, and minimal invasiveness. This study was designed 
to evaluate the long-term results of metallic self-expandable stent insertion in patients with malignant stenosis of the 
biliary tree.
Methods: It is a longitudinal study of patients with percutaneously biliary stenting from September 2005 to March 2009. 
The patients had unresectable malignant biliary obstruction with unsuccessful endoscopic stenting and access. Percuta-
neous transhepatic cholangiogram performed after adequate local anesthesia, under sonographic or fluoroscopic guid-
ance. Stenting or balloon dilation was performed through the hydrophilic guide wire. Among 50 patients, 45 stents were 
placed in biliary tree stenosis sites. Patients’ follow-up was during the first, second, third, and then the sixth month after 
insertion of biliary stents. Stent patency was considered successful in our patients, when there were no lab results or 
sonographic appearance of biliary tree obstruction.
Results: 10(20%) patients’ stent placement treatment failed because of unsuccessful technical procedure. The stenosis 
of biliary tract was complete and passage of guide wire was not possible through the tumor growth. 6 (15 %) patients 
with successful stent placements died within one month (mean, 22 days). Total serum bilirubin resolved to below 1.5 
mg/dl within 30 days for 36 (90%) patients with successful stent placements. Early complications not leading to death 
occurred in 28% of cases. The mean survival time for all patients who underwent stent placement was 140 days (16-
420days). The mean patency rate for all stents was 147 days.
Conclusions: Percutaneous biliary stenting is a safe procedure with few technical complications and a high success rate 
of palliation for patients with malignant biliary jaundice. Early complications are mostly managed conservatively and 
death is mainly due to systemic effects of the malignant disease.
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palliation  of  patients  with  obstructive  malignant 
jaundice, which is superior to plastic endoprosthesis 
when we consider the aspects of patency rate, quality 
of life, complication rate, and the cost of procedure 
(1, 2). 
In this study we decided to evaluate the long-term 
results  of  metallic  self-expandable  stent  insertion 
in patients with malignant obstructive stenosis of 
the  biliary  tree.  We  observed  the  complications, 
the  technical  and  clinical  successfulness  of  the 
procedure, and the follow-up of patients referred 
to Imaging Medical Center as a tertiary center for 
palliation therapy.
Material and Methods
This is a longitudinal study of 50 patients with 
unresectable  malignant  biliary  jaundice  who  were 
referred to our center for palliation therapy using 
nitinol self-expandable metallic stents.
All patients were evaluated at the Imaging Medical 
Center  (Imam  Khomeini  Hospital),  and  selected 
from  a  database  of  patients  between  September 
2005 and March 2009. 
The patients attending our center had unresectable 
malignant biliary obstruction; therefore, endoscopic 
retrograde  cholangiopancreatography  (ERCP)  was 
not successful or possible and endoscopic stenting 
was not performed because of lack of endoscopic 
access.
The  level  of  obstruction  was  proximal  in  40 
(80%) and distal in 10 (20%) patients.
Among 50 patients, two radiologists placed 45 
stents into the biliary tree stenosis sites. This was 
done using the percutaneous route and transhepatic 
cholangiogram. The procedure was performed after 
adequate local anesthesia, using a 22 g Chiba needle 
to access a dilated biliary duct in the right and/or left 
lobe of the liver, under sonographic or fluoroscopic 
guidance. A 0.35 mm Guide wire was then passed 
towards the porta hepatis and a tract was dilated with 
a dilator (8F). A 5F catheter was then passed over the 
0.35mm guide wire up to the obstruction site in the 
biliary duct. Next a 0.35mm hydrophilic guide wire 
was passed across the stenosis and into the common 
bile duct (CBD) and duodenum. Stenting or balloon 
dilation was performed through the hydrophilic guide 
wire  and  the  tract  was  embolized  with  GelFoam 
(Gelita Medical) or patient’s clotted blood, at the end 
of the procedure, to prevent hemorrhaging and bile 
leakage.
Balloon  dilation  of  the  strictures  in  right  or 
left  hepatic  ducts  was  performed  before  stenting 
in 14 (35%) of the patients with balloons (Boston 
Scientific, Galway, Irland) of 8mm diameters (Fig. 
1-3).
Twenty-six  (65%)  patients  underwent  stent 
placement without predilation. A total of 45 self-
expandable nitinol metallic stents (Cook Medicals, 
USA)  were  used  in  our  patients,  and  5  patients 
needed two stents for sufficient bile duct drainage 
due to obstruction of common bile duct bifurcation 
and  involvement  of  right  and  left  hepatic  ducts. 
6-8mm was the diameter of the expanded stents and 
the length was 8-10 mm.
Figure 1.  Percutaneous  transhepatic  cholangiogram 
of a patient with cholangiocarcinoma shows a severe 
stenosis of common bile duct.
Figure 2. Same patient performing balloon dilation of 
the obstruction before stenting.Hepatitis Monthly, Winter 2010; 10(1): 57-61
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Among  the  50  patients  who  were  candidates 
for  biliary  stenting,  15  (30%)  had  undergone 
percutaneous  transhepatic  cholangiogram  (PTC) 
and drainage before stent placement, with the range 
of 7 to 21 days.
Patient’s  follow-up  took  place  during  the  first, 
second,  third,  and  then  the  sixth  month  after 
insertion of biliary stents. Death was the end point 
for follow-up in this study.
Stent  patency  was  considered  successful  in 
our  patients,  when  there  were  no  lab  results  or 
sonographic appearance of biliary tree obstruction. 
In  the  case  of  recurrent  jaundice,  CT  and/or 
sonographic examinations were performed to detect 
restenosis or other complications. 
The  institutional  radiological  research  division 
of the Tehran University of Medical Sciences has 
approved this study.
A  general  physician  who  was  in  contact  with 
patients, by phone if necessary, recorded laboratory 
and clinical examinations.
Patient’s survival and stent patency were calculated 
and  descriptive  statistics  (number  and  percentage 
for  categorical  variables,  and  number,  mean,  and 
standard  deviation  for  continuous  variables)  were 
obtained using SPSS 16 software.
Results
50 patients (32 males) were included in this study 
with  the  mean  age  being  69.  They  were  referred 
to  our  center  with  primary  diagnosis  of  either 
cholangiocarcinoma (25, 50%), pancreatic carcinoma 
(20, 40%), or gallbladder cancer (5, 10%).
Ten (20%) patients failed to treat by stent placement 
because of unsuccessful technical procedure. The 
stenosis of biliary tract was completed and passage 
of guide wire was not possible through the tumor 
growth.  Six  patients  whose  stent  insertion  failed 
had  proximal  biliary  ducts  obstruction,  and  four 
had severe distal stenosis. Six (15 %) patients with 
successful stent placement died within one month 
(mean, 22 days) of treatment.
The most important cause of death during this 
period was primary advanced disease and associated 
poor conditions (four patients). Other causes were 
cardio-pulmonary  arrest  because  of  sepsis,  which 
was seen in two cases.
Total serum bilirubin resolved to below 1.5 mg/dl 
in36 (90%) patients with successful stent placement 
within 30 days. 10% of patients had no significant 
change in their serum bilirubin level. These patients 
with  unchanged  serum  bilirubin  all  died  within 
40days (16-40days) of stent insertion.
Early complications not leading to death occurred 
in 28% of cases. Complications included mild free 
fluid in the abdomen (27%), pain and nausa (45 %), 
cholangitis (9%), and hemobilia (18%), which were 
recorded during the first 30 days of post-procedure 
follow up. None of the above complications needed 
surgical or interventional treatment.
The median survival time for all patients who 
underwent stent placement was 3.3 months (95% 
confidence interval [CI] = 2.27-4.33 months). 15% 
Figure 3.  A) The situation immediately after placement 
of a metallic self-expanding biliary stent across the 
stenosis in the CBD.
B) Final result showing fully expanded CBD stent.Hepatitis Monthly, Winter 2010; 10(1): 57-61
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The  most  common  late  procedure-related 
complication  was  re-obstruction  of  the  stents  in 
patients  who  lived  more  than  90  days,  similar  to 
other studies (2), although it seems inevitable, it can 
be treated by re-intervention, at least in the majority 
of the cases. The results of multiple studies confirm 
that we could reach technical success rates of more 
than 90%. Most of the complications can be treated 
conservatively and the mortality rate of the procedure 
is significantly low (< 2%) in large series of surveys. 
In our study we had no procedure related mortalities 
(2).  All of the above could be a good reason for 
the increased usage of metallic stent placement for 
palliation of malignant biliary jaundice.
It  seems  that  pre-procedure  patient  selection 
should be considered an important factor for biliary 
stent  insertion,  especially  when  poor  condition 
suggests  uncertainty  for  surviving  more  than  a 
month. Who will be the best and benefit more from 
supportive care, and who will take more advantage 
from stent placement as a palliative treatment? We 
need to study more about the pre-procedure patient’s 
condition as there is a lack of adequate references in 
this area.
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